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LETTERS TO THE EDITOR
Immunosuppressive Treatment in Familial
Dilated Cardiomyopathy With Biopsy-proven
Intramyocardial Inflammation?
In a recent issue of the Journal, Mahon et al. (1) added substan-
tially to the pathogenesis of familial dilated cardiomyopathy
(DCM), elucidating that intramyocardial inflammation, as as-
sessed by immunohistochemical quantification of CD3
T-lymphocytes and abundance of endothelial cell adhesion mole-
cule expression (ICAM-1 and HLA-DR), is significantly present
in asymptomatic individuals with left ventricular enlargement and
who are relatives of patients with familial DCM. Their report
confirms previous findings on anticardiac autoimmunity in familial
DCM, such as autoantibodies (2) and the HLA type DR4-linked
predisposition (3). The first successful immunosuppressive study in
DCM, demonstrating beneficial long-term hemodynamic effects
over a two-year follow-up period, was based on the immunohis-
tochemical diagnosis of inflammatory cardiomyopathy (i.e., HLA
abundance) (4). In contrast, preliminary data by Chimenti et al. (5)
elucidated that only patients with biopsy-proven absence of viral
persistence will benefit from such immunosuppressive treatment.
Given the reported absence of enteroviral, adenoviral, and
cytomegaloviral genome in familial DCM (6), would the investi-
gators consider immunosuppressive treatment to prevent disease
progression in patients with established familial DCM and in their
asymptomatic relatives who have left ventricular enlargement?
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REPLY
We thank Dr. Noutsias and colleagues for their comments
regarding our report (1). Although dilated cardiomyopathy
(DCM) is classified as idiopathic, familial/genetic, viral and/or
immune (2), in the real world we lack consensus diagnostic criteria
for viral and/or immune DCM. In relation to the key question, as
to whether immunosuppression is indicated in DCM patients and
their relatives with left ventricular enlargement (LVE) (2), we
would suggest that the rational base is the establishment of
accepted consensus diagnostic criteria. This should set the ground-
work for future controlled studies of immunosuppressive therapy in
DCM. We agree with Dr. Noutsias and co-workers that autoim-
mune DCM is defined by lack of viral genome by polymerase chain
reaction (PCR) and myocardial inflammation by immunohisto-
chemistry. Although the study by Wojnicz et al. (3) has shown
beneficial hemodynamic effects of immunosuppression after two-
years, it failed to show a favorable effect on mortality, possibly
because it was statistically underpowered. Conversely, the IMAC
trial failed to demonstrate efficacy in recent-onset DCM and
myocarditis, but patients were not stratified in terms of pathogen-
esis (4). Thus, multicenter studies enrolling adequate numbers of
patients using consensus criteria for viral versus immune inflam-
mation are needed. Meanwhile, on the basis of the Polish study (3)
a short course of immunosuppression may be considered in
patients with established inflammatory DCM, with no replicating
virus. In these patients the prognosis remains poor, and the
potential benefit of halting disease progression is high.
It is, however, premature to administer immunosuppression for
asymptomatic LVE relatives with myocardial inflammation. Al-
though such therapy has the potential to prevent disease progres-
sion, the absolute risk of progression in LVE needs to be
quantified. Data from an initial cohort demonstrated progression
in 27% of subjects over three years (5), but longer follow-up in a
larger cohort is required. Second, five-year follow-up has revealed
that serum detection of cardiac-specific antibodies (6) with or
without LVE at baseline is also a noninvasive predictor of disease
progression (7). The clinical challenge is to identify more accu-
rately, ideally with noninvasive markers, asymptomatic relatives at
risk. We believe it is necessary to obtain such data before
considering a potentially deleterious therapy such as immunosup-
pression in asymptomatic relatives with preserved systolic function.
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Left Atrial Appendectomy and Maze
The feasibility and effectiveness of specific linear left atrial (LA)
lesions to treat atrial fibrillation (AF) were addressed by Kottkamp
et al. (1) in a recent issue of the Journal. Interestingly, linear lesions
confined to the left atrium were able to cure AF in more than 90%
of cases, and the technique was feasible with a minimally invasive
right mini-thoracotomy approach. Although the main objective of
AF cure is the restoration of sinus rhythm, it should be emphasized
that the most dreadful consequence of the disease is embolic
cerebrovascular accidents (CVA). Atrial fibrillation is responsible
for 20% of all strokes, and the risk of stroke is increased fivefold in
nonrheumatic AF and 17-fold in patients with mitral stenosis and
AF (2).
The efficacy of systemic anticoagulation with warfarin to reduce
the incidence of stroke has been demonstrated in randomized
clinical trials, and the left atrial appendage (LAA) has been
recognized as the source of more than 90% of emboli leading to
CVA (3,4). Fifty percent of AF patients are age 75 or older, and
it has been estimated that at least 20% have a contraindication to
warfarin treatment (5). We believe that the importance of the
LAA in the generation of embolic strokes should be addressed
when a surgical approach to AF is contemplated and, therefore, we
are concerned that the procedure proposed by Kottkamp et al. (1)
may result in higher rate of CVA as compared to the classic maze
approach, which includes LA appendectomy (6,7). It has been
demonstrated that the maze procedure is associated with three-
year 100% freedom from thromboembolic complications as com-
pared to 83% in the non-maze group (8). In the study by
Kottkamp et al. (1) surgical ablation was associated with restora-
tion of sinus rhythm and an increase in LAA flow velocity that
could potentially release occult clots into the systemic circulation.
Moreover, oral anticoagulant therapy was prescribed for at least 3
months, the mean follow-up limited to 18 months and the
incidence of CVA not mentioned.
Consequently, we would like the investigators to share their
long-term results on freedom from thromboembolism associated
with the innovative approach proposed. A minimally invasive
method for removing and/or occluding the LAA would provide a
valuable strategy for preventing stroke in patients with AF. Both
percutaneous LAA occlusion and thoracoscopic LAA amputation
have been recently developed, although further studies are needed
to confirm the safety and efficacy of these approaches (7,9).
Additional investigation is needed to determine whether LAA
obliteration, which might have a potential clinical impact similar to
carotid endarterectomy, is effective in preventing thromboembo-
lism and whether it can be advocated as a “must” in the treatment
of a selected population of patients with AF.
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We would like to thank Dr. Bonanomi and colleagues for their
interest in our work and for their thorough comments. The
spectrum of patients with atrial fibrillation (AF) is very wide and
varies from the 35-year-old manager with recurrent weekly parox-
ysms of AF resistant to antiarrhythmic drugs and severe symptoms
to the 75-year-old man with hypertension and concomitant
asymptomatic rate-controlled AF. Effective and safe treatment
strategies are available for many patients, and these often consist of
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